ERS Genomics and Japan SLC have signed a non-exclusive license agreement, allowing Japan SLC access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
ERS Genomics and Japan SLC, a biotechnology company that provides animal models to the research community, have signed a non-exclusive license agreement, allowing Japan SLC access to ERS Genomics’ clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 patent portfolio. According to a July 27, 2021 press release, through this access, Japan SLC will be able to expand its offering.
“We are proud to add Japan SLC to our growing list of partners in Japan applying CRISPR/Cas9 technology to its service offerings,” said Eric Rhodes, CEO of ERS Genomics, in the press release. “Japan SLC’s animal production and supply are of high quality, and we are very pleased that it has chosen to license CRISPR/Cas9 technology through ERS Genomics.”
“Our production and supply of laboratory animals will benefit greatly through the use of the revolutionary CRISPR/Cas9 technology,” added Hirotaka Takagi, president, Japan SLC, in the press release. “We are very excited to sign this licensing agreement with ERS Genomics which will enable us to produce CRISPR-edited mouse and rat models.”
The financial details of the non-exclusive agreement were not disclosed.
Source: ERS Genomics
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.